Prognostic factors related with survival in patients with pancreatic adenocarcinoma

World Journal of Gastroenterology

Volumn 20, Issue 31, 2014, Pages 10802-10812

  Bilici, Ahmet ^a  

^a ISTANBUL MEDIPOL UNIVERSITY   (Turkey)

Author keywords

Carbohydrate antigen 19 9; Pancreatic cancer; Prognostic factors; Survival; Treatment

Indexed keywords

ALBUMIN; BILIRUBIN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CREATININE; FLUOROURACIL; GEMCITABINE; LACTATE DEHYDROGENASE; MOLECULAR MARKER; TUMOR MARKER; ANTINEOPLASTIC AGENT;

CANCER ADJUVANT THERAPY; CANCER LOCALIZATION; CANCER PALLIATIVE THERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; DIABETES MELLITUS; HEMATOLOGICAL PARAMETERS; HISTOPATHOLOGY; HUMAN; JAUNDICE; LYMPH NODE METASTASIS; LYMPH NODE RATIO; LYMPHOCYTE COUNT; NEUTROPHIL COUNT; OBESITY; OPERATIVE BLOOD LOSS; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREATICODUODENECTOMY; PERINEURAL INVASION; PLATELET LYMPHOCYTE RATIO; PREDICTIVE VALUE; REVIEW; THROMBOCYTE COUNT; THROMBOCYTE VOLUME; TREATMENT RESPONSE; TUMOR LOCALIZATION; UREA NITROGEN BLOOD LEVEL; ADENOCARCINOMA; ADVERSE EFFECTS; BLOOD; CANCER STAGING; GENETICS; MORTALITY; PALLIATIVE THERAPY; PANCREAS RESECTION; PANCREATIC NEOPLASMS; PATHOLOGY; RISK FACTOR; SECONDARY; TIME; TREATMENT OUTCOME; TUMOR INVASION;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PALLIATIVE CARE; PANCREATECTOMY; PANCREATIC NEOPLASMS; PREDICTIVE VALUE OF TESTS; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84909646549     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i31.10802     Document Type: Review

References (90)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30 [PMID: 23335087 DOI: 10.3322/caac.21166]
2. Alexakis N, Halloran C, Raraty M, Ghaneh P, Sutton R, Neoptolemos JP. Current standards of surgery for pancreatic cancer. Br J Surg 2004; 91: 1410-1427 [PMID: 15499648 DOI: 10.1002/bjs.4794]
3. Michaud DS. Epidemiology of pancreatic cancer. Minerva Chir 2004; 59: 99-111 [PMID: 15238885]
4. Lockhart AC, Rothenberg ML, Berlin JD. Treatment for pancreatic cancer: current therapy and continued progress. Gastroenterology 2005; 128: 1642-1654 [PMID: 15887156 DOI: 10.1053/j.gastro.2005.03.039]
5. Shimada K, Sakamoto Y, Sano T, Kosuge T. Prognostic factors after distal pancreatectomy with extended lymphadenectomy for invasive pancreatic adenocarcinoma of the body and tail. Surgery 2006; 139: 288-295 [PMID: 16546491 DOI: 10.1016/j.surg.2005.08.004]
6. Boggi U, Del Chiaro M, Croce C, Vistoli F, Signori S, Moretto C, Amorese G, Mazzeo S, Cappelli C, Campani D, Mosca F. Prognostic implications of tumor invasion or adhesion to peripancreatic vessels in resected pancreatic cancer. Surgery 2009; 146: 869-881 [PMID: 19744432 DOI: 10.1016/j.surg.2009.04.029]
7. Zhang DX, Dai YD, Yuan SX, Tao L. Prognostic factors in patients with pancreatic cancer. Exp Ther Med 2012; 3: 423-432 [PMID: 22969906 DOI: 10.3892/etm.2011.412]
8. Park JK, Yoon YB, Kim YT, Ryu JK, Yoon WJ, Lee SH. Survival and prognostic factors of unresectable pancreatic cancer. J Clin Gastroenterol 2008; 42: 86-91 [PMID: 18097296 DOI: 10.1097/01.mcg.0000225657.30803.9d]
9. Wentz SC, Zhao ZG, Shyr Y, Shi CJ, Merchant NB, Washington K, Xia F, Chakravarthy AB. Lymph node ratio and preoperative CA 19-9 levels predict overall survival and recurrence-free survival in patients with resected pancreatic adenocarcinoma. World J Gastrointest Oncol 2012; 4: 207-215 [PMID: 23444312 DOI: 10.4251/wjgo.v4.i10.207]
10. Willett CG, Lewandrowski K, Warshaw AL, Efird J, Compton CC. Resection margins in carcinoma of the head of the pancreas. Implications for radiation therapy. Ann Surg 1993; 217: 144-148 [PMID: 8094952]
11. Butturini G, Stocken DD, Wente MN, Jeekel H, Klinkenbijl JH, Bakkevold KE, Takada T, Amano H, Dervenis C, Bassi C, Büchler MW, Neoptolemos JP. Influence of resection margins and treatment on survival in patients with pancreatic cancer: meta-analysis of randomized controlled trials. Arch Surg 2008; 143: 75-83; discussion 83 [PMID: 18209156 DOI: 10.1001/archsurg.2007.17]
12. Menon KV, Gomez D, Smith AM, Anthoney A, Verbeke CS. Impact of margin status on survival following pancreatoduodenectomy for cancer: the Leeds Pathology Protocol (LEEPP). HPB (Oxford) 2009; 11: 18-24 [PMID: 19590619 DOI: 10.1111/j.1477-2574.2008.00013.x]
13. Raut CP, Tseng JF, Sun CC, Wang H, Wolff RA, Crane CH, Hwang R, Vauthey JN, Abdalla EK, Lee JE, Pisters PW, Evans DB. Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Ann Surg 2007; 246: 52-60 [PMID: 17592291 DOI: 10.1097/01.sla.0000259391.84304.2b]
14. Andrén-Sandberg A. Prognostic factors in pancreatic cancer. N Am J Med Sci 2012; 4: 9-12 [PMID: 22393541 DOI: 10.4103/1947-2714.92893]
15. Berger AC, Watson JC, Ross EA, Hoffman JP. The metastatic/ examined lymph node ratio is an important prognostic factor after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am Surg 2004; 70: 235-240; discussion 240 [PMID: 15055847]
16. Pawlik TM, Gleisner AL, Cameron JL, Winter JM, Assumpcao L, Lillemoe KD, Wolfgang C, Hruban RH, Schulick RD, Yeo CJ, Choti MA. Prognostic relevance of lymph node ratio following pancreaticoduodenectomy for pancreatic cancer. Surgery 2007; 141: 610-618 [PMID: 17462460 DOI: 10.1016/j.surg.2006.12.013]
17. Riediger H, Keck T, Wellner U, zur Hausen A, Adam U, Hopt UT, Makowiec F. The lymph node ratio is the strongest prognostic factor after resection of pancreatic cancer. J Gastrointest Surg 2009; 13: 1337-1344 [PMID: 19418101 DOI: 10.1007/s11605-009-0919-2]
18. Valsangkar NP, Bush DM, Michaelson JS, Ferrone CR, Wargo JA, Lillemoe KD, Fernández-del Castillo C, Warshaw AL, Thayer SP. N0/N1, PNL, or LNR? The effect of lymph node number on accurate survival prediction in pancreatic ductal adenocarcinoma. J Gastrointest Surg 2013; 17: 257-266 [PMID: 23229885 DOI: 10.1007/s11605-012-1974-7]
19. Lee SR, Kim HO, Son BH, Yoo CH, Shin JH. Prognostic factors associated with long-term survival and recurrence in pancreatic adenocarcinoma. Hepatogastroenterology 2013; 60: 358-362 [PMID: 23574658 DOI: 10.5754/hge12727]
20. Wang PH, Song N, Shi LB, Zhang QH, Chen ZY. The relationship between multiple clinicopathological features and nerve invasion in pancreatic cancer. Hepatobiliary Pancreat Dis Int 2013; 12: 546-551 [PMID: 24103287 DOI: 10.1016/S1499-3872(13)60086-7]
21. Chatterjee D, Katz MH, Lee JE, Wolf RA, Varadhachary GR, Pisters PW. Perineural and blood vessel invasion identified after neoadjuvant treatment correlates with poor prognosis in patients with pancreatic ductal adenocarcinoma. American Pancreas Club: 45th Annual Meeting, 2011: May 6-7
22. Lee KJ, Yi SW, Chung MJ, Park SW, Song SY, Chung JB, Park JY. Serum CA 19-9 and CEA levels as a prognostic factor in pancreatic adenocarcinoma. Yonsei Med J 2013; 54: 643-649 [PMID: 23549809 DOI: 10.3349/ymj.2013.54.3.643]
23. Nagai S, Fujii T, Kodera Y, Kanda M, Sahin TT, Kanzaki A, Yamada S, Sugimoto H, Nomoto S, Takeda S, Morita S, Nakao A. Impact of operative blood loss on survival in invasive ductal adenocarcinoma of the pancreas. Pancreas 2011; 40: 3-9 [PMID: 20881897 DOI: 10.1097/MPA.0b013e3181f7147a]
24. Keck T, Wellner U, Sick O, Hopt UT. Makowiec Perioperative blood transfusions may influence prognosis after surgery for pancreatic cancer independent of complications or body mass index: Multivariate analysis of 270 resected patients. American Pancreas Club: 45th Annual Meeting, 2011: May 6-7
25. Sezgin C, Karabulut B, Uslu R, Sanli UA, Goksel G, Yuzer Y, Goker E. Gemcitabine treatment in patients with inoperable locally advanced/metastatic pancreatic cancer and prognostic factors. Scand J Gastroenterol 2005; 40: 1486-1492 [PMID: 16293561 DOI: 10.1080/00365520510023819]
26. Tas F, Sen F, Odabas H, Kilic L, Keskin S, Yildiz I. Performance status of patients is the major prognostic factor at all stages of pancreatic cancer. Int J Clin Oncol 2013; 18: 839-846 [PMID: 22996141 DOI: 10.1007/s10147-012-0474-9]
27. Kang SP, Saif MW. Clinical outcome of pancreatic cancer patients with diabetes mellitus: is diabetes a poor prognostic factor? Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010. JOP 2010; 11: 334-335 [PMID: 20601806]
28. Pannala R, Leibson CL, Rabe KG, Timmons LJ, Ransom J, de Andrade M, Petersen GM, Chari ST. Temporal association of changes in fasting blood glucose and body mass index with diagnosis of pancreatic cancer. Am J Gastroenterol 2009; 104: 2318-2325 [PMID: 19513024 DOI: 10.1038/ajg.2009.253]
29. Larsson SC, Orsini N, Wolk A. Body mass index and pancreatic cancer risk: A meta-analysis of prospective studies. Int J Cancer 2007; 120: 1993-1998 [PMID: 17266034]
30. Stolzenberg-Solomon RZ, Graubard BI, Chari S, Limburg P, Taylor PR, Virtamo J, Albanes D. Insulin, glucose, insulin resistance, and pancreatic cancer in male smokers. JAMA 2005; 294: 2872-2878 [PMID: 16352795]
31. Gong Z, Holly EA, Bracci PM. Obesity and survival in population-based patients with pancreatic cancer in the San Francisco Bay Area. Cancer Causes Control 2012; 23: 1929-1937 [PMID: 23015286 DOI: 10.1007/s10552-012-0070-3]
32. Lin Y, Fu R, Grant E, Chen Y, Lee JE, Gupta PC, Ramadas K, Inoue M, Tsugane S, Gao YT, Tamakoshi A, Shu XO, Ozasa K, Tsuji I, Kakizaki M, Tanaka H, Chen CJ, Yoo KY, Ahn YO, Ahsan H, Pednekar MS, Sauvaget C, Sasazuki S, Yang G, Xiang YB, Ohishi W, Watanabe T, Nishino Y, Matsuo K, You SL, Park SK, Kim DH, Parvez F, Rolland B, McLerran D, Sinha R, Boffetta P, Zheng W, Thornquist M, Feng Z, Kang D, Potter JD. Association of body mass index and risk of death from pancreatic cancer in Asians: findings from the Asia Cohort Consortium. Eur J Cancer Prev 2013; 22: 244-250 [PMID: 23044748 DOI: 10.1097/CEJ.0b013e3283592cef]
33. Yuan C, Bao Y, Wu C, Kraft P, Ogino S, Ng K, Qian ZR, Rubinson DA, Stampfer MJ, Giovannucci EL, Wolpin BM. Prediagnostic body mass index and pancreatic cancer survival. J Clin Oncol 2013; 31: 4229-4234 [PMID: 24145341 DOI: 10.1200/JCO.2013.51.7532]
34. Smith RA, Dajani K, Dodd S, Whelan P, Raraty M, Sutton R, Campbell F, Neoptolemos JP, Ghaneh P. Preoperative resolution of jaundice following biliary stenting predicts more favourable early survival in resected pancreatic ductal adenocarcinoma. Ann Surg Oncol 2008; 15: 3138-3146 [PMID: 18787902 DOI: 10.1245/s10434-008-0148-z]
35. Perini MV, Montagnini AL, Jukemura J, Penteado S, Abdo EE, Patzina R, Cecconello I, Cunha JE. Clinical and pathologic prognostic factors for curative resection for pancreatic cancer. HPB (Oxford) 2008; 10: 356-362 [PMID: 18982152 DOI: 10.1080/13651820802140752]
36. Strasberg SM, Gao F, Sanford D, Linehan DC, Hawkins WG, Fields R, Carpenter DH, Brunt EM, Phillips C. Jaundice: an important, poorly recognized risk factor for diminished survival in patients with adenocarcinoma of the head of the pancreas. HPB (Oxford) 2014; 16: 150-156 [PMID: 23600768 DOI: 10.1111/hpb.12094]
37. Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, Beger H, Fernandez-Cruz L, Dervenis C, Lacaine F, Falconi M, Pederzoli P, Pap A, Spooner D, Kerr DJ, Büchler MW. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004; 350: 1200-1210 [PMID: 15028824 DOI: 10.1056/NEJMoa032295]
38. Regine WF, Winter KA, Abrams RA, Safran H, Hoffman JP, Konski A, Benson AB, Macdonald JS, Kudrimoti MR, Fromm ML, Haddock MG, Schaefer P, Willett CG, Rich TA. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA 2008; 299: 1019-1026 [PMID: 18319412 DOI: 10.1001/jama.299.9.1019]
39. Thomas A, Dajani K, Neoptolemos JP, Ghaneh P. Adjuvant therapy in pancreatic cancer. Dig Dis 2010; 28: 684-692 [PMID: 21088421 DOI: 10.1159/000320099]
40. Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D, Padbury R, Moore MJ, Gallinger S, Mariette C, Wente MN, Izbicki JR, Friess H, Lerch MM, Dervenis C, Oláh A, Butturini G, Doi R, Lind PA, Smith D, Valle JW, Palmer DH, Buckels JA, Thompson J, McKay CJ, Rawcliffe CL, Büchler MW. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 2010; 304: 1073-1081 [PMID: 20823433 DOI: 10.1001/jama.2010.1275]
41. Bünger S, Laubert T, Roblick UJ, Habermann JK. Serum biomarkers for improved diagnostic of pancreatic cancer: a current overview. J Cancer Res Clin Oncol 2011; 137: 375-389 [PMID: 21193998 DOI: 10.1007/s00432-010-0965-x]
42. Duffy MJ, Sturgeon C, Lamerz R, Haglund C, Holubec VL, Klapdor R, Nicolini A, Topolcan O, Heinemann V. Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report. Ann Oncol 2010; 21: 441-447 [PMID: 19690057 DOI: 10.1093/annonc/mdp332]
43. Shah UA, Saif MW. Tumor markers in pancreatic cancer: 2013. JOP 2013; 14: 318-321 [PMID: 23846917]
44. Kim YC, Kim HJ, Park JH, Park DI, Cho YK, Sohn CI, Jeon WK, Kim BI, Shin JH. Can preoperative CA19-9 and CEA levels predict the resectability of patients with pancreatic adenocarcinoma? J Gastroenterol Hepatol 2009; 24: 1869-1875 [PMID: 19686409 DOI: 10.1111/j.1440-1746.2009.05935.x]
45. Koom WS, Seong J, Kim YB, Pyun HO, Song SY. CA 19-9 as a predictor for response and survival in advanced pancreatic cancer patients treated with chemoradiotherapy. Int J Radiat Oncol Biol Phys 2009; 73: 1148-1154 [PMID: 18760544 DOI: 10.1016/j.ijrobp.2008.06.1483]
46. Stocken DD, Hassan AB, Altman DG, Billingham LJ, Bramhall SR, Johnson PJ, Freemantle N. Modelling prognostic factors in advanced pancreatic cancer. Br J Cancer 2008; 99: 883-893 [PMID: 19238630 DOI: 10.1038/sj.bjc.6604568]
47. Humphris JL, Chang DK, Johns AL, Scarlett CJ, Pajic M, Jones MD, Colvin EK, Nagrial A, Chin VT, Chantrill LA, Samra JS, Gill AJ, Kench JG, Merrett ND, Das A, Musgrove EA, Sutherland RL, Biankin AV. The prognostic and predictive value of serum CA19.9 in pancreatic cancer. Ann Oncol 2012; 23: 1713-1722 [PMID: 22241899 DOI: 10.1093/annonc/mdr561]
48. Carriquiry LA, Piñeyro A. Should carcinoembryonic antigen be used in the management of patients with colorectal cancer? Dis Colon Rectum 1999; 42: 921-929 [PMID: 10411440]
49. Louhimo J, Alfthan H, Stenman UH, Haglund C. Serum HCG beta and CA 72-4 are stronger prognostic factors than CEA, CA 19-9 and CA 242 in pancreatic cancer. Oncology 2004; 66: 126-131 [PMID: 15138364 DOI: 10.1159/000077438]
50. Donskov F, von der Maase H. Impact of immune parameters on long-term survival in metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 1997-2005 [PMID: 16648500 DOI: 10.1200/JCO.2005.03.9594]
51. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, Rubin SC, Coukos G. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003; 348: 203-213 [PMID: 12529460 DOI: 10.1056/NEJMoa020177]
52. Fumagalli LA, Vinke J, Hoff W, Ypma E, Brivio F, Nespoli A. Lymphocyte counts independently predict overall survival in advanced cancer patients: a biomarker for IL-2 immunotherapy. J Immunother 2003; 26: 394-402 [PMID: 12973028]
53. Sierko E, Wojtukiewicz MZ. Platelets and angiogenesis in malignancy. Semin Thromb Hemost 2004; 30: 95-108 [PMID: 15034801 DOI: 10.1055/s-2004-822974]
54. Schwarz RE, Keny H. Preoperative platelet count predicts survival after resection of periampullary adenocarcinoma. Hepatogastroenterology 2001; 48: 1493-1498 [PMID: 11677994]
55. Domínguez I, Crippa S, Thayer SP, Hung YP, Ferrone CR, Warshaw AL, Fernández-Del Castillo C. Preoperative platelet count and survival prognosis in resected pancreatic ductal adenocarcinoma. World J Surg 2008; 32: 1051-1056 [PMID: 18224462 DOI: 10.1007/s00268-007-9423-6]
56. Stotz M, Gerger A, Eisner F, Szkandera J, Loibner H, Ress AL, Kornprat P, AlZoughbi W, Seggewies FS, Lackner C, Stojakovic T, Samonigg H, Hoefler G, Pichler M. Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer. Br J Cancer 2013; 109: 416-421 [PMID: 23799847 DOI: 10.1038/bjc.2013.332]
57. Aliustaoglu M, Bilici A, Seker M, Dane F, Gocun M, Konya V, Ustaalioglu BB, Gumus M. The association of pre-treatment peripheral blood markers with survival in patients with pancreatic cancer. Hepatogastroenterology 2010; 57: 640-645 [PMID: 20698242]
58. Smith RA, Bosonnet L, Raraty M, Sutton R, Neoptolemos JP, Campbell F, Ghaneh P. Preoperative platelet-lymphocyte ratio is an independent significant prognostic marker in resected pancreatic ductal adenocarcinoma. Am J Surg 2009; 197: 466-472 [PMID: 18639229 DOI: 10.1016/j.amjsurg.2007.12.057]
59. Tas F, Aykan F, Alici S, Kaytan E, Aydiner A, Topuz E. Prognostic factors in pancreatic carcinoma: serum LDH levels predict survival in metastatic disease. Am J Clin Oncol 2001; 24: 547-550 [PMID: 11801751]
60. Haas M, Heinemann V, Kullmann F, Laubender RP, Klose C, Bruns CJ, Holdenrieder S, Modest DP, Schulz C, Boeck S. Prognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: results from a multicenter, pooled analysis of patients receiving palliative chemotherapy. J Cancer Res Clin Oncol 2013; 139: 681-689 [PMID: 23315099 DOI: 10.1007/s00432-012-1371-3]
61. Damaraju VL, Damaraju S, Young JD, Baldwin SA, Mackey J, Sawyer MB, Cass CE. Nucleoside anticancer drugs: the role of nucleoside transporters in resistance to cancer chemotherapy. Oncogene 2003; 22: 7524-7536 [PMID: 14576856 DOI: 10.1038/sj.onc.1206952]
62. Farrell JJ, Elsaleh H, Garcia M, Lai R, Ammar A, Regine WF, Abrams R, Benson AB, Macdonald J, Cass CE, Dicker AP, Mackey JR. Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology 2009; 136: 187-195 [PMID: 18992248 DOI: 10.1053/j.gastro.2008.09.067]
63. Xiao JC, Zhang TP, Zhao YP. Human equilibrative nucleoside transporter 1 (hENT1) predicts the Asian patient response to gemcitabine-based chemotherapy in pancreatic cancer. Hepatogastroenterology 2013; 60: 258-262 [PMID: 23574652 DOI: 10.5754/hge12687]
64. Neoptolemos JP, Greenhalf W, Ghaneh P, Palmer DH, Cox TF, Garner E, Campbell F, Mackey JR, Moore MJ, Valle JW, Mcdonald A, Tebbutt NC, Dervenis C, Glimelius B, Charnley RM, Lacaine F, Mayerle J, Rawcliffe CL, Bassi C, Buchler MV.HENT1 tumor levels to predict survival of pancreatic ductal adenocarcinoma patients who received adjuvant gemcitabine and adjuvant 5FU on the ESPAC trials. J Clin Oncol 2013; (Suppl): Abstract 4006
65. Puolakkainen PA, Brekken RA, Muneer S, Sage EH. Enhanced growth of pancreatic tumors in SPARC-null mice is associated with decreased deposition of extracellular matrix and reduced tumor cell apoptosis. Mol Cancer Res 2004; 2: 215-224 [PMID: 15140943]
66. Tang MJ, Tai IT. A novel interaction between procaspase 8 and SPARC enhances apoptosis and potentiates chemotherapy sensitivity in colorectal cancers. J Biol Chem 2007; 282: 34457-34467 [PMID: 17897953 DOI: 10.1074/jbc.M704459200]
67. Hidalgo M, Von Hoff DD. Translational therapeutic opportunities in ductal adenocarcinoma of the pancreas. Clin Cancer Res 2012; 18: 4249-4256 [PMID: 22896691 DOI: 10.1158/1078-0432.CCR-12-1327]
68. Sinn M, Sinn BV, Striefler JK, Lindner JL, Stieler JM, Lohneis P, Bischoff S, Bläker H, Pelzer U, Bahra M, Dietel M, Dörken B, Oettle H, Riess H, Denkert C. SPARC expression in resected pancreatic cancer patients treated with gemcitabine: results from the CONKO-001 study. Ann Oncol 2014; 25: 1025-1032 [PMID: 24562449]
69. Negin BP, Meropol NJ, Alpaugh RK, Ruth K, McAleer C, Halbherr T, Bingham C, Fittipaldi P, Cohen SJ. Characterization and prognostic significance of circulating tumor cells in the peripheral blood of patients with metastatic pancreatic cancer. J Clin Oncol 2010; (Suppl): Abstract 4127
70. Bidard FC, Huguet F, Louvet C, Mineur L, Bouché O, Chibaudel B, Artru P, Desseigne F, Bachet JB, Mathiot C, Pierga JY, Hammel P. Circulating tumor cells in locally advanced pancreatic adenocarcinoma: the ancillary CirCe 07 study to the LAP 07 trial. Ann Oncol 2013; 24: 2057-2061 [PMID: 23676420]
71. Oikonomopoulos GM, Syrigos KN, Saif MW. Prognostic factors in pancreatic cancer. JOP 2013; 14: 322-324 [PMID: 23846918 DOI: 10.6092/1590-8577/1644]
72. Fink SP, Mikkola D, Willson JK, Markowitz S. TGF-betainduced nuclear localization of Smad2 and Smad3 in Smad4 null cancer cell lines. Oncogene 2003; 22: 1317-1323 [PMID: 12618756]
73. Hahn SA, Schutte M, Hoque AT, Moskaluk CA, da Costa LT, Rozenblum E, Weinstein CL, Fischer A, Yeo CJ, Hruban RH, Kern SE. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 1996; 271: 350-353 [PMID: 8553070]
74. Tascilar M, Skinner HG, Rosty C, Sohn T, Wilentz RE, Offerhaus GJ, Adsay V, Abrams RA, Cameron JL, Kern SE, Yeo CJ, Hruban RH, Goggins M. The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma. Clin Cancer Res 2001; 7: 4115-4121 [PMID: 11751510 DOI: 10.1158/1078-0432.CCR-09-0227]
75. Biankin AV, Morey AL, Lee CS, Kench JG, Biankin SA, Hook HC, Head DR, Hugh TB, Sutherland RL, Henshall SM. DPC4/Smad4 expression and outcome in pancreatic ductal adenocarcinoma. J Clin Oncol 2002; 20: 4531-4542 [PMID: 12454109 DOI: 10.1200/JCO.2002.12.063]
76. Blackford A, Serrano OK, Wolfgang CL, Parmigiani G, Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Eshleman JR, Goggins M, Jaffee EM, Iacobuzio-Donahue CA, Maitra A, Cameron JL, Olino K, Schulick R, Winter J, Herman JM, Laheru D, Klein AP, Vogelstein B, Kinzler KW, Velculescu VE, Hruban RH. SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer. Clin Cancer Res 2009; 15: 4674-4679 [PMID: 19584151]
77. Oshima M, Okano K, Muraki S, Haba R, Maeba T, Suzuki Y, Yachida S. Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer. Ann Surg 2013; 258: 336-346 [PMID: 23470568 DOI: 10.1097/SLA.0b013e3182827a65]
78. Singh P, Srinivasan R, Wig JD. SMAD4 genetic alterations predict a worse prognosis in patients with pancreatic ductal adenocarcinoma. Pancreas 2012; 41: 541-546 [PMID: 22504380 DOI: 10.1097/MPA.0b013e318247d6af]
79. Couvelard A, O'Toole D, Turley H, Leek R, Sauvanet A, Degott C, Ruszniewski P, Belghiti J, Harris AL, Gatter K, Pezzella F. Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression. Br J Cancer 2005; 92: 94-101 [PMID: 15558070 DOI: 10.1038/sj.bjc.6602245]
80. Sun HC, Qiu ZJ, Liu J, Sun J, Jiang T, Huang KJ, Yao M, Huang C. Expression of hypoxia-inducible factor-1 alpha and associated proteins in pancreatic ductal adenocarcinoma and their impact on prognosis. Int J Oncol 2007; 30: 1359-1367 [PMID: 17487356]
81. Tao J, Li T, Li K, Xiong J, Yang Z, Wu H, Wang C. Effect of HIF-1alpha on VEGF-C induced lymphangiogenesis and lymph nodes metastases of pancreatic cancer. J Huazhong Univ Sci Technolog Med Sci 2006; 26: 562-564 [PMID: 17219968]
82. Hoffmann AC, Mori R, Vallbohmer D, Brabender J, Klein E, Drebber U, Baldus SE, Cooc J, Azuma M, Metzger R, Hoelscher AH, Danenberg KD, Prenzel KL, Danenberg PV. High expression of HIF1a is a predictor of clinical outcome in patients with pancreatic ductal adenocarcinomas and correlated to PDGFA, VEGF, and bFGF. Neoplasia 2008; 10: 674-679 [PMID: 18592007]
83. Little JL, Serzhanova V, Izumchenko E, Egleston BL, Parise E, Klein-Szanto AJ, Loudon G, Shubina M, Seo S, Kurokawa M, Ochs MF, Golemis EA. A requirement for Nedd9 in luminal progenitor cells prior to mammary tumorigenesis in MMTV-HER2/ErbB2 mice. Oncogene 2014; 33: 411-420 [PMID: 23318423 DOI: 10.1038/onc.2012.607]
84. Kim M, Gans JD, Nogueira C, Wang A, Paik JH, Feng B, Brennan C, Hahn WC, Cordon-Cardo C, Wagner SN, Flotte TJ, Duncan LM, Granter SR, Chin L. Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene. Cell 2006; 125: 1269-1281 [PMID: 16814714 DOI: 10.1016/j.cell.2006.06.008]
85. Kondo S, Iwata S, Yamada T, Inoue Y, Ichihara H, Kichikawa Y, Katayose T, Souta-Kuribara A, Yamazaki H, Hosono O, Kawasaki H, Tanaka H, Hayashi Y, Sakamoto M, Kamiya K, Dang NH, Morimoto C. Impact of the integrin signaling adaptor protein NEDD9 on prognosis and metastatic behavior of human lung cancer. Clin Cancer Res 2012; 18: 6326-6338 [PMID: 23037767 DOI: 10.1158/1078-0432.CCR-11-2162]
86. Xue YZ, Sheng YY, Liu ZL, Wei ZQ, Cao HY, Wu YM, Lu YF, Yu LH, Li JP, Li ZS. Expression of NEDD9 in pancreatic ductal adenocarcinoma and its clinical significance. Tumour Biol 2013; 34: 895-899 [PMID: 23247867 DOI: 10.1007/s13277-012-0624-8]
87. Wierstra I. FOXM1 (Forkhead box M1) in tumorigenesis: overexpression in human cancer, implication in tumorigenesis, oncogenic functions, tumor-suppressive properties, and target of anticancer therapy. Adv Cancer Res 2013; 119: 191-419 [PMID: 23870513 DOI: 10.1016/B978-0-12-407190-2.00016-2]
88. Xia JT, Wang H, Liang LJ, Peng BG, Wu ZF, Chen LZ, Xue L, Li Z, Li W. Overexpression of FOXM1 is associated with poor prognosis and clinicopathologic stage of pancreatic ductal adenocarcinoma. Pancreas 2012; 41: 629-635 [PMID: 22249132 DOI: 10.1097/MPA.0b013e31823bcef2]
89. Tsiaousidou A, Lambropoulou M, Chatzitheoklitos E, Tripsianis G, Tsompanidou C, Simopoulos C, Tsaroucha AK. B7H4, HSP27 and DJ-1 molecular markers as prognostic factors in pancreatic cancer. Pancreatology 2013; 13: 564-569 [PMID: 24280570 DOI: 10.1016/j.pan.2013.10.005]
90. Perini MV, Montagnini AL, Coudry R, Patzina R, Penteado S, Abdo EE, Diniz A, Jukemura J, da Cunha JE. Prognostic significance of epidermal growth factor receptor overexpression in pancreas cancer and nodal metastasis. ANZ J Surg 2013; Epub ahead of print [PMID: 24112413 DOI: 10.1111/ans.12399]